Research

Energy balance

Availability of semaglutide in Medicare for all FDA-approved indications would yield net savings ranging from $1.04 billion to $412 million over 10 years.

Healthcare providers should advocate for the inclusion of semaglutide in Medicare to maximize economic and health benefits.

StrongSupportsmedium confidence
Availability of semaglutide in Medicare for all FDA-approved indications would have a substantial impact on health outcomes at net savings of between $1.04 billion and $412 million over 10 years.
Victoria Dayer et al. · Value in Health · 2025

Why this rating

The study uses a comprehensive approach to estimate savings based on various scenarios.

Source

Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare

Victoria Dayer et al. · Value in Health · 2025

DOI 10.1016/j.jval.2025.07.007

otherCited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →